Q2 2026 saw 30% sales growth at constant exchange rates, strong cash flow, and a 29% adjusted operating margin. U.S. and EUROW segments both delivered robust growth, with guidance for full-year sales growth raised to 33%-36%. Key catalysts include CMS reimbursement, SOLARIO study, and CERAMENT V ap…
Q2 2026 saw 30% sales growth at constant exchange rates, strong cash flow, and a 29% adjusted operating margin. U.S. and EUROW segments both delivered robust growth, with guidance for full-year sales growth raised to 33%-36%. Key catalysts include CMS reimbursement, SOLARIO study, and CERAMENT V approval.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
